Elena Reigadas

Dr. Elena Reigadas


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MKMarcela Krutova
Marcela Krutova
PKP. Kinross
P. Kinross
FBF. Barbut
F. Barbut
AHA. Hajdu
A. Hajdu
MWM.H. Wilcox
M.H. Wilcox
TMT. Morris
T. Morris

1 January 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MAMercedes Marin Arriaza
Mercedes Marin Arriaza
AMAdoración Martín
Adoración Martín
LALuis Alcalá
Luis Alcalá
ECEmilia Cercenado
Emilia Cercenado
CICristina Iglesias
Cristina Iglesias
EBEmilio Bouza
Emilio Bouza
We studied the molecular mechanisms of linezolid resistance in 9 isolates of toxigenic Clostridium difficile with high linezolid MICs. The activity of linezolid was determined against 891 clinical isolates of toxigenic C. difficile . The MIC 50 and MIC 90 of linezolid were 0.75 μg/ml and 1.5 μg/ml, respectively. Nine strains (1%) showed high linezolid MICs (6 μg/ml to 16 μg/ml) and also were resistant to clindamycin, erythromycin, and chloramphenicol. These strains were selected for molecular studies: sequencing of domain V of the 23 rRNA gene, detection of the cfr methyltransferase gene, and sequencing of the ribosomal protein genes rplC and rplD . Molecular relatedness between strains was assessed using PCR ribotyping and MLVA (multilocus variable-number tandem-repeat analysis) typing. The strains belonged to ribotypes 001 (2/9), 017 (6/9), and 078 (1/9). MLVA showed that strains of ribotype 001 and 017 belonged to the same clonal complex in each ribotype. We did not detect mutations in the 23S rRNA gene. The cfr gene was detected in 7 of 9 strains. Sequencing of cfr amplicons revealed a similarity of 100% to a fragment of transposon Tn 6218 of C. difficile , which was annotated as a putative chloramphenicol/florfenicol resistance protein. We were unable to detect mechanisms of resistance to linezolid in the 2 strains belonging to ribotype 001. While the relevance of our results lies in the detection of the cfr gene as a possible mechanism of resistance to linezolid in C. difficile , our findings should be assessed by further investigations to characterize these possible cfr genes and their contribution to linezolid resistance.

24 April 2015 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
OGon behalf of the Spanish Clostridium difficile Study Group
on behalf of the Spanish Clostridium difficile Study Group
LALuis Alcala
Luis Alcala
ERElena Reigadas
Elena Reigadas
MMM. Marín
M. Marín
AMA. Martín
A. Martín
EBE. Bouza
E. Bouza

10 February 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
ERElena Reigadas
Elena Reigadas
LAL. Alcalá
L. Alcalá
MVM. Valerio
M. Valerio
MMM. Marín
M. Marín
AMA. Martin
A. Martin
EBE. Bouza
E. Bouza
Prediction of patients with poor outcome is necessary in order to plan the proper management of Clostridium difficile infection (CDI); however, clinical criteria are insufficient. In a previous study, we observed that high toxigenic C. difficile cfu stool counts at diagnosis were associated with a poor outcome. Our objective was to investigate the role of the PCR toxin B amplification cycle threshold (Ct) in the prediction of CDI poor outcome and to derive and validate a high-risk prediction rule using this marker. We prospectively included patients with CDI (derivation cohort, January 2013 to June 2014; and validation cohort, December 2014 to May 2015), who were followed for at least 2 months after their last episode/recurrence. All samples were tested with Xpert™ C. difficile. For the derivation cohort (n = 129) toxin B Ct was independently associated with poor outcome (P < 0.001). The receiver operating characteristic (ROC) curve yielded an AUC of 0.816. Using a cut-off of <23.5 cycles for high risk of poor outcome, the diagnostic accuracy was 81.4%, the sensitivity was 46.5% (95% CI 32.5–61.1) and the specificity was 98.8% (95% CI 93.7–99.8). For the validation cohort (n = 170), the diagnostic accuracy was 81.8%, the sensitivity was 88.4% (95% CI 75.5–94.9) and the specificity was 79.5% (95% CI 71.7–85.6). The ROC curve yielded an AUC of 0.857. Low toxin B Ct values from samples collected at the initial moment of diagnosis appears to be a strong marker for poor outcome. This available test may identify, at an early stage, patients who are at higher risk of a poor outcome CDI.

16 August 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JDJudith Díaz-García
Judith Díaz-García
AGAna Gómez
Ana Gómez
LALuis Alcalá
Luis Alcalá
ERElena Reigadas
Elena Reigadas
CSCarlos Sánchez-Carrillo
Carlos Sánchez-Carrillo
Jesus GuineaJesus Guinea
Jesus Guinea
We have been monitoring the antifungal resistance in Candida parapsilosis isolates collected from inpatients at Madrid metropolitan area hospitals for the last 3 years. The study aimed to elucidate the presence of fluconazole-resistant C. parapsilosis genotypes in Madrid.

1 August 2013 in Anaerobe
Verified
Journal Article
Closed access
MRMaria Teresa Peláez García de la Rasilla
Maria Teresa Peláez García de la Rasilla
LALuis Alcalá
Luis Alcalá
JBJosé L. BLANCO
José L. BLANCO
SASergio Alvarez-Perez
Sergio Alvarez-Perez
MMMercedes Marín
Mercedes Marín
EBEmilio Bouza
Emilio Bouza